


FORM PTO-1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO. P1614-7038
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		DATE: August 4, 1997	
		U.S. APPLN. NO. <i>08/875603</i>	
INTERNATIONAL APPLICATION NO. PCT/EP96/00498	INTERNATIONAL FILING DATE February 7, 1996	PRIORITY DATE CLAIMED February 8, 1995	
TITLE OF INVENTION: USE OF CARBAZOLE COMPOUNDS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE			
APPLICANT(S) FOR DO/EO/US: Mary Ann LUKAS-LASKEY, Robert RUFFOLO, Jr., Neil SHUSTERMANN, Gisbert SPONER and Klaus STREIN			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information: PCT/IPEA/401, PCT/IPEA/416, PCT/IPEA/409, PCT/RO/105, PCT/RO/101, PCT/ISA/210, PCT/ISA/220 Check No. 14073</p>			

U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.50)		INTERNATIONAL APPLICATION NO. PCT/EP96/00498		ATTORNEY DOCKET NO. P1614-7038
				DATE: August 4, 1997
<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>Basic National Fee (37 CFR 1.492(a)(1)-(5):</p> <p>Search Report has been prepared by the EPO or JPO.....\$910.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482)....\$700.00</p> <p>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$770.00</p> <p>Neither international preliminary examination fee (37 CFR 1.482) or international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)</p>				CALCULATIONS
				PTO USE ONLY
<p>ENTER APPROPRIATE BASIC FEE AMOUNT = 6</p>				\$910.00
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(e)).</p>				\$0
Claims	Number Filed	Number Extra	Rate	
Total Claims	27 - 20 =	7	X \$ 22.00	\$154.00
Independent Claims	6 - 3 =	3	X \$ 80.00	\$240.00
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$0
TOTAL OF ABOVE CALCULATIONS =				\$1,304.00
<p>Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).</p>				\$0
SUBTOTAL =				\$1,304.00
<p>Processing fee of \$130.00 for furnishing the English translation later the <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(f)).</p>				\$0
TOTAL NATIONAL FEE =				\$1,304.00
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</p>				\$0
TOTAL FEES ENCLOSED =				\$1,304.00
				Amount to be refunded \$
				Charged \$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1,304.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>14-1060</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>14-1060</u>.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>				
<p>SEND ALL CORRESPONDENCE TO:</p> <p>NIKAIKO, MARMELSTEIN, MURRAY AND ORAM Metropolitan Square 655 15th Street, N.W. Suite 330 - G Street Lobby Washington, D.C. 20005-5701 Telephone No. (202) 638-5000</p>				




Robert B. Murray
Reg. No. 22,980

103 Rec'd PCT/PTO 29 DEC 1997

154-130

#3

FORM PTO-1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO. P1614-7038
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		DATE: December 29, 1997	
		U.S. APPLN. NO. (IF KNOWN, SEE 37 CFR 1.5) 08/875,603	
INTERNATIONAL APPLICATION NO. PCT/EP96/00498	INTERNATIONAL FILING DATE February 7, 1996	PRIORITY DATE CLAIMED February 8, 1995	
TITLE OF INVENTION: USE OF CARBAZOLE COMPOUNDS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE			
APPLICANT(S) FOR DO/EO/US: Mary Ann LUKAS-LASKEY, Robert RUFFOLO, Jr., Neil SHUSTERMAN, Gisbert SPONER and Klaus STREIN			
<p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. (THE BASIC FILING FEE IS ATTACHED)</p> <p>2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>01/11/1998 ADDED BY 10000501007545 Inventor(s) (35 U.S.C. 371(c)(4)). 01 PC:154 130.00 OP</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information: Notification of Missing Requirements, one month Extension of Time Check No. 15389</p>			

U.S. APPLN. NO. (IF KNOWN, SEE 37 C.F.R. 1.50) 08/875,603		INTERNATIONAL APPLICATION NO. PCT/EP96/00498		ATTORNEY DOCKET NO. P1614-7038
				DATE: December 29, 1997
<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>Basic National Fee (37 CFR 1.492(a)(1)-(5):</p> <p>Search Report has been prepared by the EPO or JPO.....\$910.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)....\$700.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$770.00 Neither international preliminary examination fee (37 CFR 1.482) or international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$ 96.00</p>				CALCULATIONS PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT = 6				\$00
Surcharge of \$130.00 for furnishing the oath or declaration later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(e)).				\$130
Claims	Number Filed	Number Extra	Rate	
Total Claims	27 - 20 =	7	X \$ 22.00	\$00
Independent Claims	6 - 3 =	3	X \$ 80.00	\$00
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$00
TOTAL OF ABOVE CALCULATIONS =				\$00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$00
SUBTOTAL =				\$130.00
Processing fee of \$130.00 for furnishing the English translation later the <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(f)). +				\$0
TOTAL NATIONAL FEE =				\$130.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$40
TOTAL FEES ENCLOSED =				\$170.00
				Amount to be refunded \$
				Charged \$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$280 to cover the above fees and the one month Extension of Time is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>14-1060</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>14-1060</u>.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>				
<p>SEND ALL CORRESPONDENCE TO:</p> <p>NIKAIDO, MARMELSTEIN, MURRAY AND ORAM Metropolitan Square 655 15th Street, N.W. Suite 330 - G Street Lobby Washington, D.C. 20005-5701 Telephone No. (202) 638-5000</p>				
 Robert B. Murray Reg. No. 22,980				

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

LUKAS-LASKEY, et al.

Serial Number: New Appln.

Filed: August 4, 1997

For: USE OF CARBAZOLE COMPOUNDS FOR THE TREATMENT OF CONGESTIVE
HEART FAILURE

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

August 4, 1997

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 1-14 without prejudice or disclaimer.


Please add new claims 15 - 41 as follows:

--15. A method of treating to decrease mortality resulting from congestive heart failure in a patient in need of such treatment, said method comprising administering to said patient a congestive heart failure mortality decreasing effective amount of a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist alone or in combination with at least one other therapeutic agent.

16. A method as recited in claim 15, wherein said patient is a mammal.

17. A method as recited in claim 15, further comprising administering to said patient at least one other therapeutic agent selected from the group consisting of angiotensin converting enzyme inhibitors, diuretics and cardiac glycosides.

18. A method as recited in claim 15, wherein said compound is a compound of formula I:



wherein:

R₁ is hydrogen, lower alkanoyl of from 1 to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;

R₂ is hydrogen, lower alkyl of from 1 to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;

R₃ is hydrogen or lower alkyl of from 1 to 6 carbon atoms;

R_4 is hydrogen or lower alkyl of from 1 to 6 carbon atoms, or, where X is oxygen, R_4 together with R_5 can also be $-CH_2-O-$

X is a valency bond, $-CH_2-$, oxygen or sulfur;

Ar is phenyl, naphthyl, indanyl or tetrahydronaphthyl;

R_5 and R_6 are individually selected from hydrogen, fluorine, chlorine, bromine hydroxyl, lower alkyl of from 1 to 6 carbon atoms, a $-CONH_2$ group, lower alkoxy of from 1 to 6 carbon atoms, benzyloxy, lower alkylthio of from 1 to 6 carbon atoms and lower alkylsulphonyl of from 1 to 6 carbon atoms; or R_5 and R_6 together represent methylenedioxy;

or a pharmaceutically acceptable salt thereof.

19. A method as recited in claim 18, further comprising administering to said patient at least one other therapeutic agent selected from the group consisting of angiotensin converting enzyme inhibitors, diuretics and cardiac glycosides.

20. A method as recited in claim 15, wherein said compound is carvedilol.

21. A method as recited in claim 17, wherein said compound is carvedilol.

22. A method as recited in claim 15, wherein said step of administering comprises administering to said patient unit dosages once or twice daily, for a period of from 7 to 28 days, said unit dosages each comprising a pharmaceutical formulation comprising carvedilol in an amount of

about 3.125 mg or about 6.25 mg.

23. A method as recited in claim 15, wherein said step of administering comprises administering to said patient unit dosages once or twice daily, for a period of from 7 to 28 days, said unit dosages each comprising a pharmaceutical formulation comprising about 12.5 mg of carvedilol.

24. A method as recited in claim 15, wherein said step of administering comprises administering to said patient unit dosages once or twice daily, each said unit dosage comprising a pharmaceutical formulation comprising carvedilol in an amount of about 25.0 mg or about 50.0 mg.

25. A method as recited in claim 15, wherein said step of administering comprises administering to said patient daily dosages of said compound in an amount of from about 1.0 mg to about 30.0 mg.

26. A method as recited in claim 15, wherein said step of administering comprises administering to said patient daily dosages of said compound in an amount of from about 2.0 mg to about 70.0 mg.

27. A method as recited in claim 15, wherein said step of administering comprises administering to said patient daily dosages of said compound in an amount of from about 10.0 mg to about 100.0 mg.

28. A method as recited in claim 17, wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of captopril, lisinopril, fosinopril, enalapril and pharmaceutically acceptable salts of captopril, lisinopril, fosinopril and enalapril.

29. A method as recited in claim 17, wherein said diuretic is selected from the group consisting of hydrochlorothiazide, torasemide, furosemide, and pharmaceutically acceptable salts of hydrochlorothiazide, torasemide and furosemide.

30. A method as recited in claim 17, wherein said cardiac glycoside is selected from the group consisting of digoxin, β -methyl-digoxin and digitoxin.

31. A method of treating congestive heart failure in a patient in need of such treatment, said method comprising administering to said patient first dosages once or twice daily, for a period of from 7 to 28 days, said first dosages each comprising a pharmaceutical formulation comprising carvedilol in an amount of about 3.125 mg or about 6.25 mg,

then administering to said patient second dosages once or twice daily, for a period of from 7 to 28 days, said second dosages each comprising a pharmaceutical formulation comprising carvedilol in an amount of about 12.5 mg, and

then administering to said patient third dosages once or twice daily, for a period of at least one day, said third dosages each comprising a pharmaceutical formulation comprising carvedilol in an amount of about 25.0 mg or about 50.0 mg.

32. A method as recited in claim 31, wherein at least one of said first, second and third dosages further comprise at least one other therapeutic agent selected from the group consisting of angiotensin converting enzyme inhibitors, diuretics and cardiac glycosides.

33. A method of treating congestive heart failure in a patient in need of such treatment, said method comprising:

administering to said patient first dosages daily for a period of from 7 to 28 days, said first dosages each comprising at least one pharmaceutical formulation comprising a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist,

then administering to said patient second dosages daily for a period of from 7 to 28 days, said second dosages each comprising at least one pharmaceutical formulation comprising a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist, once a day for a period of from 7 to 28 days, and

then administering to said patient third dosages daily for a period of at least one day, said third dosages each comprising at least one pharmaceutical formulation comprising a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist, said third dosages each comprising a daily maintenance dose in the range of from about 10 mg to about 100 mg of the compound,

said first dosages each comprising the compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist in an amount which is 10-30% of said daily maintenance dose,

said second dosages each comprising the compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist in an amount which is 20-70% of said daily

maintenance dose.


34. A unit dosage oral pharmaceutical formulation comprising 1.0 - 10.0 mg carvedilol.

35. A unit dosage oral pharmaceutical formulation as recited in claim 34, wherein said formulation comprises 2.5 - 7.5 mg carvedilol.

36. A pharmaceutical formulation comprising:

a congestive heart failure treating effective amount of a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist for decreasing mortality; and at least one other therapeutic agent selected from the group consisting of angiotensin converting enzyme inhibitors, diuretics and cardiac glycosides.

37. A pharmaceutical formulation as recited in claim 36, wherein said compound is a compound according to formula I:



wherein:

R_1 is hydrogen, lower alkanoyl of from 1 to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;

R_2 is hydrogen, lower alkyl of from 1 to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;

R_3 is hydrogen or lower alkyl of from 1 to 6 carbon atoms;

R_4 is hydrogen or lower alkyl of from 1 to 6 carbon atoms, or, where X is oxygen, R_4 together with R_5 can also be $-\text{CH}_2\text{-O-}$

X is a valency bond, $-\text{CH}_2-$, oxygen or sulfur;

Ar is phenyl, naphthyl, indanyl or tetrahydronaphthyl;

R_5 and R_6 are individually selected from hydrogen, fluorine, chlorine, bromine hydroxyl, lower alkyl of from 1 to 6 carbon atoms, a $-\text{CONH}_2$ group, lower alkoxy of from 1 to 6 carbon atoms, benzyloxy, lower alkylthio of from 1 to 6 carbon atoms and lower alkylsulphonyl of from 1 to 6 carbon atoms; or R_5 and R_6 together represent methylenedioxy;


or a pharmaceutically acceptable salt thereof.

38. A pharmaceutical formulation as recited in claim 36, wherein said compound is carvedilol.

39. A kit comprising:

unit dosages of a congestive heart failure treating effective amount of a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonist for decreasing mortality; and unit dosages of at least one other therapeutic agent selected from the group consisting of angiotensin converting enzyme inhibitors, diuretics and cardiac glycosides.

40. A kit as recited in claim 39, wherein said compound is a compound according to formula I:



wherein:

- R_1 is hydrogen, lower alkanoyl of from 1 to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
- R_2 is hydrogen, lower alkyl of from 1 to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;
- R_3 is hydrogen or lower alkyl of from 1 to 6 carbon atoms;
- R_4 is hydrogen or lower alkyl of from 1 to 6 carbon atoms, or, where X is oxygen, R_4

together with R₅ can also be -CH₂-O-

X is a valency bond, -CH₂-, oxygen or sulfur;

Ar is phenyl, naphthyl, indanyl or tetrahydronaphthyl;

R₅ and R₆ are individually selected from hydrogen, fluorine, chlorine, bromine hydroxyl, lower alkyl of from 1 to 6 carbon atoms, a -CONH₂ group, lower alkoxy of from 1 to 6 carbon atoms, benzyloxy, lower alkylthio of from 1 to 6 carbon atoms and lower alkylsulphonyl of from 1 to 6 carbon atoms; or R₅ and R₆ together represent methylenedioxy;

or a pharmaceutically acceptable salt thereof.

41. A kit as recited in claim 39, wherein said compound is carvedilol.--

REMARKS

Claims 15 - 41 are added and original claims 1 - 14 are canceled in order to present claims which more particularly define the claimed subject matter, and to present claims which conform with formal U.S. requirements.

Favorable consideration of claims 15 - 41 is solicited.

Should it be deemed that any further action by the applicants could place this application in better condition for allowance, the Examiner is invited to telephone the undersigned at the number listed below.

In the event this paper is not timely filed, applicants hereby petition for an appropriate

extension of time. The fee for this extension may be charged to our Deposit Account No. 14-1060, along with any other additional fees which may be required with respect to this paper.

Should any additional fees be due with respect to this paper, such fees may be charged to Counsel's Deposit Account No. 14-1060.

Respectfully submitted,

NIKAIDO, MARMELSTEIN, MURRAY & ORAM LLP



Kevin C. Brown
Attorney for Applicant
Registration No. 32,402

Atty. Docket No. P1614-7038
Metropolitan Square
655 Fifteenth Street, N.W.
Suite 330 - G-Street Lobby
Washington, D.C. 20005-5701
(202) 638-5000
KCB/dr

84ccd PCT/PTO 04 AUG 1997.

5 USE OF CARBAZOLE COMPOUNDS FOR THE TREATMENT OF
CONGESTIVE HEART FAILURE**Field of the Invention**

10

The present invention relates to a new method of treatment using compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists, in particular the carbazolyl-(4)-oxypropanolamine compounds of Formula I, preferably carvedilol, for decreasing the mortality of patients suffering from congestive heart failure (CHF). The 15 invention also relates to a method of treatment using compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists, in particular the carbazolyl-(4)-oxypropanolamine compounds of Formula I, preferably carvedilol, in conjunction with one or more other therapeutic agents, said agents being selected from the group 20 consisting of angiotensin converting enzyme (ACE) inhibitors, diuretics, and cardiac glycosides, for decreasing the mortality of patients suffering from CHF. The invention further relates to an incremental application scheme for administering compounds which 25 are β -adrenoreceptor and α_1 -adrenoreceptor antagonists.

Background of the Invention

25

Congestive heart failure occurs as a result of impaired pumping capability of the heart and is associated with abnormal retention of water and sodium. Traditionally, treatment of chronic mild failure has included limitation of physical activity, restriction of salt intake, and the use of a diuretic. If these measures are not sufficient, a cardiac glycoside, 30 which is an agent that increases the force of myocardial contraction, is typically added to the treatment regimen.

- 2 -

Subsequently, angiotensin converting enzyme inhibitors, which are compounds that prevent the conversion of angiotensin I into the pressor-active angiotensin II, are prescribed for chronic treatment of congestive heart failure, in conjunction with a diuretic, a cardiac glycoside, or both.

5

Also, congestive heart failure is a well-known cardiac disorder which results in an excess mortality. Applefeld, M.M., (1986) Am. J. Med., 80, Suppl. 2B, 73-77. Therefore, therapeutic agents that would decrease the mortality resulting from CHF in patients suffering therefrom are highly desirable.

10


Summary of the Invention

The present invention provides a new use of compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists for the preparation of medicaments for 15 the treatment of congestive heart failure. In particular, the carbazolyl-(4)-oxypropanol-amine compounds of Formula I are preferred, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and cardiac glycosides, as therapeutics for decreasing mortality resulting from congestive heart failure in mammals, particular. In particular, the present 20 invention preferably provides a method of treatment, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and cardiac glycosides, for the compound of Formula I wherein R_1 is -H, R_2 is -H, R_3 is -H, R_4 is -H, X is 0, Ar is phenyl, R_5 is ortho - $0CH_3$, and R_6 is -H, said compound being better known as carvedilol, which is (1-(carbazol-4-yloxy- 25 3-[[2-(2-methoxyphenoxy) ethyl]amino]2-propanol), or a pharmaceutically acceptable salt thereof.

- 3 -

Detailed Description of the Invention

U.S. Pat. No. 4,503,067 discloses carbazolyl-(4)-oxypropanolamine compounds of Formula I:



(I)

5

wherein

R₁ is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;

10 R₂ is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;

R₃ is hydrogen or lower alkyl of up to 6 carbon atoms;

15 R₄ is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R₄ together with R₅ can represent -CH₂-O-;

X is a valency bond, -CH₂, oxygen or sulfur;

20 Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;


- 4 -

R₅ and R₆ are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a -CONH₂- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkylsulphonyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms;

5 or

R₅ and R₆ together represent methylenedioxy; and pharmaceutically acceptable salts thereof.

10 This patent further discloses a compound of Formula I, better known as carvedilol, which is (1-(carbazol-4-yloxy-3-[[2-(2-methoxyphenoxy)ethyl]amino](2-propanol), having the structure shown in Formula II:



15 Formula I compounds, of which carvedilol is exemplary, are novel multiple action drugs useful in the treatment of mild to moderate hypertension. Carvedilol is known to be both a competitive non-selective β -adrenoceptor antagonist and a vasodilator, and is also a calcium channel antagonist at higher concentrations. The vasodilatory actions of carvedilol result primarily from α_1 -adrenoceptor blockade, whereas the β -adrenoceptor blocking activity of the drug prevents reflex tachycardia when used in the treatment of

20 hypertension. These multiple actions of carvedilol are responsible for the antihypertensive efficacy of the drug in animals, particularly in humans. See Willette, R.N., Sauer-melch, C.F. & Ruffolo, R.R., Jr. (1990) *Eur. J. Pharmacol.*, 176, 237-240; Nichols, A.J., Gellai, M. & Ruffolo, R.R., Jr. (1991) *Fundam. Clin. Pharmacol.*, 5, 25-38; Ruffolo,

- 5 -

R.R., Jr., Gellai, M., Hieble, J.P., Willette, R.N. & Nichols, A.J. (1990) Eur. J. Clin. Pharmacol., 38, S82-588; Ruffolo, R.R., Jr., Boyle, D.A., Venuti, R.P. & Lukas, M.A. (1991) Drugs of Today, 27, 465-492; and Yue, T.-L., Cheng, H., Lysko, P.G., McKenna, P.J., Feuerstein, R., Gu, I., Lysko, K.A., Davis, L.L. & Feuerstein, G. (1992) J. Pharmacol. Exp. Ther., 263, 92-98.

The antihypertensive action of carvedilol is mediated primarily by decreasing total peripheral vascular resistance without causing the concomitant reflex changes in heart rate commonly associated with other antihypertensive agents. Willette, R.N., et al. supra; 10 Nichols, A.J., et al. supra; Ruffolo, R.R., Jr., Gellai, M., Hieble, J.P., Willette, R.N. & Nichols, A.J. (1990) Eur. J. Clin. Pharmacol., 38, S82-S88. Carvedilol also markedly reduces infarct size in rat, canine and porcine models of acute myocardial infarction. Ruffolo, R.R., Jr., et al., Drugs of Today, supra, possibly as a consequence of its 15 antioxidant action in attenuating oxygen free radical-initiated lipid peroxidation. Yue, T.-L., et al. supra.

Recently, it has been discovered in clinical studies that pharmaceutical compounds which are dual non-selective β -adrenoceptor and α_1 -adrenoceptor antagonists, in particular the compounds of Formula I, preferably carvedilol, alone or in conjunction with conventional 20 agents, said agents being ACE inhibitors, diuretics, and cardiac glycosides, are effective therapeutic agents for treating CHF. The use of agents, such as carvedilol in treating CHF is surprising, since, in general, β -blockers are contraindicated in patients suffering from heart failure, because β -blockers are known to have undesirable cardiodepressive effects. The most surprising observation from the studies in which the instant compounds 25 were used to treat CHF is that said compounds, in particular carvedilol, are able to decrease the mortality resulting from CHF in humans by about 67 percent. Furthermore, this result is present across all classifications of CHF and both etiologies (eschemic and non-eschemic). This result is surprising since two recent mortality studies using the β -blockers metoprolol (Waagstein, et al., (1993) Lancet, 342, 1441-1446) and bisoprolol 30 (CIBIS investigators and committees, (1994) Circulation, 90, 1765-1773) in the

- 6 -

treatment of CHF showed no difference in mortality between drug-treated patients and placebo-treated patients.

According to the method of treatment of the present invention, the desirable therapeutic effect of the compounds of Formula I, particularly carvedilol, may be augmented by using any one of said compounds; or any pharmaceutically acceptable salt of said compounds, in conjunction with ACE inhibitors, diuretics, and cardiac glycosides, which are effective therapeutic agents for the treatment of CHF. In particular, the preferred ACE inhibitors of the present invention are selected from the group consisting of captopril, lisinopril, fosinopril and enalapril, or any pharmaceutically acceptable salts thereof and the preferred diuretics of the present invention are hydrochlorothiazide furosemide, or torasemide or any pharmaceutically acceptable salts thereof. The preferred cardiac glycosides of the present invention are digoxin, β -methyldigoxin or digitoxin. The desirable therapeutic benefits of the compounds of Formula I, particularly carvedilol, are additive with those of such ACE inhibitors, or diuretics, or cardiac glycosides when administered in combination therewith. Captopril is commercially available from E.R. Squibb & Sons, Inc. Lisinopril, enalapril and hydrochlorothiazide are commercially available from Merck & Co. Furosemide is commercially available from Hoechst-Roussel Pharmaceuticals, Inc. Digoxin is commercially available from Burroughs Wellcome Co. and Boehringer Mannheim GmbH. Digitoxin, β -Methyldigoxin, fosinopril and torasemide are commercially available from Boehringer Mannheim GmbH.

Compounds of Formula I may be conveniently prepared as described in U.S. Pat. No. 4,503,067. Carvedilol is commercially available from SmithKline Beecham Corporation and Boehringer Mannheim GmbH (Germany).

Pharmaceutical compositions of the compounds of Formula I, including carvedilol, alone or in combination with ACE inhibitors, or diuretics, or cardiac glycosides may be administered to patients according to the present invention in any medically acceptable manner, preferably orally. For parenteral administration, the pharmaceutical composition will be in the form of a sterile injectable liquid stored in a suitable container such as an

- 7 -

ampoule, or in the form of an aqueous or nonaqueous liquid suspension. The nature and composition of the pharmaceutical carrier, diluent or excipient will, of course, depend on the intended route of administration, for example whether by intravenous or intramuscular injection.

5

Pharmaceutical compositions of the compounds of Formula I for use according to the present invention may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a
10 buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as ethanol, polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium
15 chloride or sodium citrate.

Alternatively, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may
20 be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl
25 distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will
30 be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.

Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

Compounds having the above-mentioned dual properties are preferably administered
5 following a three-stage application scheme. This scheme is characterized by the fact that incremental dosages of the active ingredient are administered to patients over a certain period of time, until the regular maintenance dosage is received. If this maintenance dosage is defined as the setting value being 100 %, it was found that the application regimen in a first phase should extend for a period of 7 - 28 days, whereby only 10-30 %
10 of the setting dose are administered. Following this phase, a second application regimen should follow, wherein a dosage of 20 - 70 % of the setting dose is administered to the patient for a period of 7 - 28 days. After termination of this phase, the third application period follows, wherein the daily complete setting dose (maintenance dose) is administered. The daily maintenance dose can vary between 10 - 100 mg of said active
15 ingredient.

In case of carvedilol, dosing in humans for the treatment of disease according to the present invention should not exceed a dosage range of from about 3.125 to about 50 mg of the compounds of Formula I, particularly carvedilol, preferably given twice daily. As
20 one of ordinary skill in the art will readily comprehend, the patient should be started on a low dosage regimen of the desired compound of Formula I, particularly carvedilol, and monitored for well-known symptoms of intolerance, e.g., fainting, to such compound. Once the patient is found to tolerate such compound, the patient should be brought slowly and incrementally up to the maintenance dose. The preferred course of treatment
25 is to start the patient on a dosage regimen with formulations which contain either 3.125 or 6.25 mg of active compound per single unit, preferably given twice daily, for 7 - 28 days. The choice of initial dosage most appropriate for the particular patient is determined by the practitioner using well-known medical principles, including, but not limited to, body weight. In the event that the patient exhibits medically acceptable
30 tolerance of the compound for two weeks, the dosage is doubled at the end of the two weeks and the patient is maintained at the new, higher dosage for an additional period.

- 9 -

preferably to two more weeks, and observed for signs of intolerance. This course is continued until the patient is brought to a maintenance dose. The preferred maintenance dose is 25.0 mg of active compound per single unit, preferably given twice daily, for patients having a body weight of up to 85 kg. For patients having a body weight of over 5 85 kg, the maintenance dose is between about 25.0 mg and about 50.0 mg, preferably given twice daily; preferably about 50.0 mg of active compound per single unit, preferably given twice daily.

10 The present invention relates also to method of treatment for decreasing mortality resulting from congestive heart failure in mammals comprising internally administering to said mammal in need thereof an effective amount of carvedilol according to the following schedule:

- 15 (a) a pharmaceutical formulation which contains either 3.125 or 6.25 mg carvedilol per single unit for a period of 7 - 28 days, given once or twice daily.
- 20 (b) thereafter a pharmaceutical formulation which contains 12.5 mg carvedilol per single unit for a period of additional 7 - 28 days, given once or twice daily, and
- (c) finally a pharmaceutical formulation which contains either 25.0 or 50.0 mg carvedilol per single unit, given once or twice daily as a maintenance dose.

Dosing in humans for the treatment of disease according to the present invention includes the combination of compounds of Formula I with conventional agents. For example, the usual adult dosage of hydrochlorothiazide is 25 - 100 mg daily as a single dose or divided dose. The recommended starting dose for enalapril is 2.5 mg administered once or twice daily. The usual therapeutic dosing range for enalapril is 5 - 20 mg daily, given as a single dose or two divided doses. For most patients the usual initial daily dosage of captopril is 25 mg three times per day (tid), with most patients having a 25 satisfactory clinical improvement at 50 or 100 mg three times per day (tid).

- 10 -

It will be appreciated that the actual preferred dosages of the compounds being used in the compositions of this invention will vary according to the particular composition formulated, the mode of administration, the particular site of administration and the host being treated.

5

No unacceptable toxicological effects are expected when the compounds of Formula I, including the compound of Formula II, are used according to the present invention. The example which follows is intended in no way to limit the scope of this invention, but is provided to illustrate how to use the compounds of this invention. Many other embodiments will be readily apparent to those skilled in the art.

Experimental

15 Mortality Studies in CHF Patients

Summary. To determine if β -adrenergic blockade might inhibit the deleterious effects of the sympathetic nervous system on survival in heart failure (CHF), 1052 patients with CHF were prospectively enrolled into a multicenter trial program, in which patients were randomly assigned (double-blind) to 6-12 months' treatment with placebo (PBO) or carvedilol (CRV). After a common screening period, patients with class II-IV CHF (see next paragraph for the definitions of the classification of CI) and an ejection fraction < 0.35 were assigned to one of four protocols based on performance on a 6-minute walk test. PBO or CRV was added to existing therapy with digoxin, diuretics and an ACE inhibitor. All-cause mortality was monitored by a prospectively constituted Data and Safety Monitoring Board (DSMB). After 25 months of enrollment, the DSMB recommended termination of the program because of a favorable effect of CRV on survival. By intention-to-treat, mortality was 8.2% in the PBO group but only 2.9% in the CRV group ($P = 0.0001$, Cochran-Mantel-Haensel analysis). This represented a reduction in risk of death by CRV of 67% (95% CI: 42% to 81%). The treatment effect

- 11 -

was similar in patients with class II and class III-IV symptoms. Mortality was reduced in class II patients from 5.9% to 1.9%, a 68% reduction (95% CI: 20% to 97%) [P = 0.015,], and in class III-IV patients from 11.0% to 4.2%, a 67% reduction (95% CI: 30% to 84%), [P = 0.004, log-rank]. Importantly, the effect of CRV was similar in 5 ischemic heart disease (risk reduced by 67%, P = 0.003) and in nonischemic dilated cardiomyopathy (risk reduced by 67%, P = 0.014). In conclusion, the addition of CRV to conventional therapy is associated with a substantial (67%) reduction in the mortality of patients with chronic CHF. The treatment effect is seen across a broad range of severity and etiology of disease.

10

As used herein, by "Class II CHF" is meant patients with cardiac disease resulting in slight or moderate limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. By "Class III CHF" is meant patients with cardiac disease resulting in marked limitations of physical 15 activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. By "Class IV CI" is meant patients with cardiac disease resulting in inability to carry on any physical activity without discomfort, symptoms or cardiac insufficiency, or of the anginal syndrome. By "less than ordinary physical activity" is meant climbing one flight of stairs, or walking two hundred yards.

20

Design of Study. Patients on background therapy with diuretics, ACE inhibitors and/or digoxin were stratified on the basis of baseline submaximal exercise performance, into one of four trials:

25

- study 220, a dose response study in moderate (NYHA II-IV) CHF with exercise testing as a primary endpoint
- study 221, a dose titration study in moderate (NYHA II-IV) CI with exercise testing as a primary endpoint

30

- 12 -

- study 239, a dose titration study in severe (NYHA III-IV) CHF with quality of life as a primary endpoint
- study 240, a dose titration study in mild (NYHA II-III) CHF with progression of CHF as a primary endpoint

5 Sixty-four centers in the US participated in the trial program. All sites conducted protocols 239 and 240, while 33 performed protocol 220 and 31 performed protocol 221.

10

15 Although each trial had its own individual objectives, the overall program objective defined prospectively was evaluation of all-cause mortality. Based upon a projected enrollment of 1100 patients, the program had 90% power to detect a 50% reduction in mortality (two-sided) between carvedilol and placebo, assuming a mortality rate in the placebo group of 12% over the duration of the trials $\alpha = 0.05$.

20 Randomization was preceded by a screening and challenge period common to the four protocols. The purpose of the screening period was to qualify patients for study entry, obtain reproducible baseline measurements, and stratify patients into the appropriate trial based on submaximal exercise testing. During the challenge period, patients received low-dose open-label carvedilol (6.25 mg b.i.d.) for two weeks. Patients unable to tolerate this dose did not proceed to randomization. Patients tolerating low-dose carvedilol were then randomized to blinded medication (carvedilol or placebo) with the dose titrated over several weeks in the range of 6.25 to 50 mg b.i.d. (or equivalent level 25 of placebo). The maintenance phase of each study ranged from six to 12 months, after which patients had the option of receiving open-label carvedilol in an extension study.

30 **Results.** The analysis presented below corresponds to the data set on which the DSMB made the recommendation to terminate the trials. Included in this intent-to-eat analysis are all patients enrolled in the US trials as of January 20, 1995; 624 receiving carvedilol

- 13 -

and 356 placebo. An analysis of baseline patient characteristics (Table 1) shows good balance between the randomized groups.

5 **Table 1:** US Carvedilol Heart Failure Trials - Baseline Characteristics

Characteristic	Placebo (n = 356)	Carvedilol (n = 624)
Age, mean + SD (years)	59.9+11.7	58.8+11.8
Sex (% men)	62%	62%
Etiology (% ischemic)	43%	40%
Severity of CHF		
Class II	41%	41%
Class III-IV	40%	39%
Unknown	19%	20%
LV ejection fraction, mean + SD	0.22 + 0.07	0.23 + 0.08
6 Minute walk (m + SD)	373+88	379+81
Blood pressure (mmHg)	115/73	115/73
Heart rate (bpm + SD)	85 ± 13	86 ± 13

The overall mortality results for the program are shown in Table 2. All deaths that occurred during the intent-to-treat period are included. Treatment with carvedilol 10 resulted in a 67% reduction in the risk of all-cause mortality. Analysis of mortality by certain baseline characteristics shows this to be a broad effect regardless of severity or etiology of CI. The effect was uniform in patients with mild heart failure or moderate to severe heart failure. Similarly, the mortality reduction was equivalent in patients with ischemic or non-ischemic heart failure.

Table 2: Evaluation of Mortality in US Carvedilol CHF Studies

	Carvedilol	Placebo	Risk reduction (95 % CI)	p value*
All Cause Mortality	18/624 (2.9 %)	29/356 (8.2 %)	67 % (42 - 81)	< 0.001
Class II CHF	7/361 (1.9 %)	12/202 (5.9 %)	68 % (20 - 97)	0.015
Class III-IV CHF	11/263 (4.2 %)	17/154 (11.0 %)	66 % (30 - 84)	0.004
Ischemic Etiology	10/311 (3.2 %)	16/178 (8.9 %)	67 % (32 - 85)	0.003
Non-Ischemic Etiology	8/313 (2.5 %)	13/178 (7.3 %)	67 % (20 - 86)	0.014

*Cochran-Mantel-Haensel Analysis

5 The foregoing is illustrative of the use of the compounds of this invention. This invention, however, is not limited to the precise embodiment described herein, but encompasses all modifications within the scope of the claims which follow.

- 15 -


Claims

1. The use of a compound which is both a β -adrenoreceptor antagonist and a α_1 -adrenoreceptor antagonists for the manufacture of a medicament for decreasing mortality resulting from congestive heart failure in mammals, alone or in conjunction with one or more other therapeutic agents, said agents selected from the group consisting of an angiotensin converting enzyme inhibitor, a diuretic and a cardiac glycosides

5

2. The use of a compound according to claim 1, wherein said compound is subject of formula I

10



(I)

wherein

15

R_1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;

20

R_2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;

R_3 is hydrogen or lower alkyl of up to 6 carbon atoms;

- 16 -

R₄ is hydrogen or lower alkyl of up to 6 carbon atoms. or when X is oxygen. R₄ together with R₅ can represent -CH₂-0-.

X is a valency bond, -CH₂, oxygen or sulfur;

5

Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;

R₅ and R₆ are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a -CONH₂- group, lower 10 alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkylsulphonyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or

R₅ and R₆ together represent methylenedioxy; and pharmaceutically acceptable 15 salts thereof.

- 3 The use of a compound according to claim 1 or 2, wherein said compound is carvedilol
- 20 4. The use of a compound according to claim 3, whereby a pharmaceutical formulation containing either 3.125 or 6.25 mg carvedilol in a single unit are administered for a period of 7 - 28 days, once or twice daily as an initial dose.
- 25 5. The use of a compound according to claim 3, whereby a pharmaceutical formulation containing 12.5 mg carvedilol in a single unit are administered for a period of 7 - 28 days, once or twice daily.
- 30 6. The use of a compound according to claim 3, whereby a pharmaceutical formulation containing either 25.0 or 50.0 mg carvedilol in a single unit are administered once or twice as a maintenance dose.

- 17 -

7 The use of a compound according to claim 1, wherein said ACE inhibitor is selected from the group consisting of captopril, lisinopril, fosinopril or enalapril, or any pharmaceutically acceptable salt thereof.

5 8 The use of a compound according to claim 1, wherein said diuretic is selected from the group consisting of hydrochlorothiazide, torasemide or furosemide, or any pharmaceutically acceptable salt thereof.

9 The use of a compound according to claim 1, wherein said cardiac glycoside is 10 selected from the group consisting of digoxin, β -methyl-digoxin or digitoxin.

10 The use of carvedilol for the manufacture of a medicament for decreasing mortality resulting from congestive heart failure in mammals according to the following regimen:

15 (a) administering a pharmaceutical formulation which contains either 3.125 or 6.25 mg carvedilol per single unit for a period of 7 - 28 days, given once or twice daily.

20 (b) administering thereafter a pharmaceutical formulation which contains 12.5 mg carvedilol per single unit for a period of additional 7 - 28 days, given once or twice daily and

25 (c) administering finally a pharmaceutical formulation which contains either 25.0 or 50.0 mg carvedilol per single unit, given once or twice daily as a maintenance dose.

11. The use of carvedilol according to claim 10, whereby carvedilol is administered in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of an angiotensin converting enzyme inhibitor, a diuretic and a cardiac glycoside.

5

12. Use of a compound according to claim 1 for the preparation of a medicament for the treatment of CHF to be administered in a daily maintenance dose of 10 - 100 mg, said medicament being administered in incremental dosage schemes comprising three dose regimens, the first regimen comprising administering an amount of 10 - 30 % of the daily maintenance dose of the compound for a period of 7 - 28 days, the second regimen comprising administering an amount of 20 - 70 % of said daily dose for a period of 7 - 28 days and a third regimen comprising administering 100 % of said daily dose starting after termination of the second regimen.

10

Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention **entitled** (Insert Title) **USE OF CARBAZOLE COMPOUNDS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE** the specification of which is attached hereto unless the following box is checked:

was filed on February 7, 1996 as United States Application Number or PCT International Application Number PCT/EP96/00498 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International Application having a filing date before that of the application(s) for which priority is claimed:

(List prior foreign applications. See note A on back of this page)	<u>195 03 995.5</u> (Number)	<u>DE</u> (Country)	<u>8/2/95</u> (Day/Month/Year Filed)	Priority Claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<input type="checkbox"/> Yes <input type="checkbox"/> No
	<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

<u>(Application Number)</u>	<u>(Filing Date)</u>
<u>(Application Number)</u>	<u>(Filing Date)</u>

(See Note B on back of this page)

See attached list for additional prior foreign or provisional applications.

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) (U.S. or PCT) in the manner provided by the first paragraph of 35, U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(List prior U.S. Applications or PCT International applications designating the U.S.)	<u>08/483,635</u> (Application Serial No.)	<u>7/6/95</u> (Filing Date)	<u>(Status) (patented, pending, abandoned)</u>
	<u>(Application Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status) (patented, pending, abandoned)</u>

And I hereby appoint as principal attorneys David T. Nikaido, Reg. No. 22,663; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Robert B. Murray, Reg. No. 22,980; Martin S. Postman, Reg. No. 18,570; E. Marcie Emas, Reg. No. 32,131; Douglas H. Goldhush, Reg. No. 33,125; Kevin C. Brown, Reg. No. 32,402; Monica Chin Kitts, Reg. No. 36,105; Sharon N. Klesner, Reg. No. 36,335; and Richard J. Berman, Reg. No. 39,107.

Please direct all communications to the following address:

NIKAIKO, MARMELSTEIN, MURRAY & ORAM LLP

Metropolitan Square

655 Fifteenth Street, N.W., Suite 330 - G Street Lobby

Washington, D.C. 20005-5701

(202) 638-5000 Fax: (202) 638-4810

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(See Note C on back of this page)

Full name of sole or first inventor Mary Ann LUKAS-LASKEY

Inventor's signature Mary Ann Lukas-Laskey

Residence 1019 Great Springs Road, Rosemont, PA 19010, U.S.A. PA


Citizenship U.S.A.

Post Office Address Same as above

12/3/99

Date

200 Full name of second joint inventor, if any Robert RUFFO L.O.

Inventor's signature 

Residence 725 Pughtown Road, Spring City, PA 19475 U.S.A. P.P.


Citizenship U.S.A.

Post Office Address Same as above

12/1/97

Date

300 Full name of third joint inventor, if any Neil SHUSTERMAN

Inventor's signature 

Dec 1, 1997


Date

Residence 451 Ballytore Road, Wynnewood, PA 19096, U.S.A. P.P.

Citizenship U.S.A.

Post Office Address Same as above

Full name of fourth joint inventor, if any Gisbert SPONER

Inventor's signature 

Dec 1, 1997


Date

Residence Lessingstrasse 13, D-69514 Laudenbach, Germany

Citizenship German

Post Office Address Same as above

Full name of fifth joint inventor, if any Klaus STREIN

Inventor's signature 

Dec 12, 1997

Date

Residence Eichenstrasse 45, D-69503 Hemsbach, Germany

Citizenship German

Post Office Address Same as above

200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800 2900 3000 3100 3200 3300 3400 3500 3600 3700 3800 3900 4000 4100 4200 4300 4400 4500 4600 4700 4800 4900 5000 5100 5200 5300 5400 5500 5600 5700 5800 5900 6000 6100 6200 6300 6400 6500 6600 6700 6800 6900 7000 7100 7200 7300 7400 7500 7600 7700 7800 7900 8000 8100 8200 8300 8400 8500 8600 8700 8800 8900 9000 9100 9200 9300 9400 9500 9600 9700 9800 9900 10000 10100 10200 10300 10400 10500 10600 10700 10800 10900 11000 11100 11200 11300 11400 11500 11600 11700 11800 11900 12000 12100 12200 12300 12400 12500 12600 12700 12800 12900 13000 13100 13200 13300 13400 13500 13600 13700 13800 13900 14000 14100 14200 14300 14400 14500 14600 14700 14800 14900 15000 15100 15200 15300 15400 15500 15600 15700 15800 15900 16000 16100 16200 16300 16400 16500 16600 16700 16800 16900 17000 17100 17200 17300 17400 17500 17600 17700 17800 17900 18000 18100 18200 18300 18400 18500 18600 18700 18800 18900 19000 19100 19200 19300 19400 19500 19600 19700 19800 19900 20000 20100 20200 20300 20400 20500 20600 20700 20800 20900 21000 21100 21200 21300 21400 21500 21600 21700 21800 21900 22000 22100 22200 22300 22400 22500 22600 22700 22800 22900 23000 23100 23200 23300 23400 23500 23600 23700 23800 23900 24000 24100 24200 24300 24400 24500 24600 24700 24800 24900 25000 25100 25200 25300 25400 25500 25600 25700 25800 25900 26000 26100 26200 26300 26400 26500 26600 26700 26800 26900 27000 27100 27200 27300 27400 27500 27600 27700 27800 27900 28000 28100 28200 28300 28400 28500 28600 28700 28800 28900 29000 29100 29200 29300 29400 29500 29600 29700 29800 29900 30000 30100 30200 30300 30400 30500 30600 30700 30800 30900 31000 31100 31200 31300 31400 31500 31600 31700 31800 31900 32000 32100 32200 32300 32400 32500 32600 32700 32800 32900 33000 33100 33200 33300 33400 33500 33600 33700 33800 33900 34000 34100 34200 34300 34400 34500 34600 34700 34800 34900 35000 35100 35200 35300 35400 35500 35600 35700 35800 35900 36000 36100 36200 36300 36400 36500 36600 36700 36800 36900 37000 37100 37200 37300 37400 37500 37600 37700 37800 37900 38000 38100 38200 38300 38400 38500 38600 38700 38800 38900 39000 39100 39200 39300 39400 39500 39600 39700 39800 39900 40000 40100 40200 40300 40400 40500 40600 40700 40800 40900 41000 41100 41200 41300 41400 41500 41600 41700 41800 41900 42000 42100 42200 42300 42400 42500 42600 42700 42800 42900 43000 43100 43200 43300 43400 43500 43600 43700 43800 43900 44000 44100 44200 44300 44400 44500 44600 44700 44800 44900 45000 45100 45200 45300 45400 45500 45600 45700 45800 45900 46000 46100 46200 46300 46400 46500 46600 46700 46800 46900 47000 47100 47200 47300 47400 47500 47600 47700 47800 47900 48000 48100 48200 48300 48400 48500 48600 48700 48800 48900 49000 49100 49200 49300 49400 49500 49600 49700 49800 49900 50000 50100 50200 50300 50400 50500 50600 50700 50800 50900 51000 51100 51200 51300 51400 51500 51600 51700 51800 51900 52000 52100 52200 52300 52400 52500 52600 52700 52800 52900 53000 53100 53200 53300 53400 53500 53600 53700 53800 53900 54000 54100 54200 54300 54400 54500 54600 54700 54800 54900 55000 55100 55200 55300 55400 55500 55600 55700 55800 55900 56000 56100 56200 56300 56400 56500 56600 56700 56800 56900 57000 57100 57200 57300 57400 57500 57600 57700 57800 57900 58000 58100 58200 58300 58400 58500 58600 58700 58800 58900 58900 59000 59100 59200 59300 59400 59500 59600 59700 59800 59900 60000 60100 60200 60300 60400 60500 60600 60700 60800 60900 61000 61100 61200 61300 61400 61500 61600 61700 61800 61900 62000 62100 62200 62300 62400 62500 62600 62700 62800 62900 63000 63100 63200 63300 63400 63500 63600 63700 63800 63900 64000 64100 64200 64300 64400 64500 64600 64700 64800 64900 65000 65100 65200 65300 65400 65500 65600 65700 65800 65900 66000 66100 66200 66300 66400 66500 66600 66700 66800 66900 67000 67100 67200 67300 67400 67500 67600 67700 67800 67900 68000 68100 68200 68300 68400 68500 68600 68700 68800 68900 68900 69000 69100 69200 69300 69400 69500 69600 69700 69800 69900 70000 70100 70200 70300 70400 70500 70600 70700 70800 70900 71000 71100 71200 71300 71400 71500 71600 71700 71800 71900 72000 72100 72200 72300 72400 72500 72600 72700 72800 72900 72900 73000 73100 73200 73300 73400 73500 73600 73700 73800 73900 73900 74000 74100 74200 74300 74400 74500 74600 74700 74800 74900 74900 75000 75100 75200 75300 75400 75500 75600 75700 75800 75900 75900 76000 76100 76200 76300 76400 76500 76600 76700 76800 76900 76900 77000 77100 77200 77300 77400 77500 77600 77700 77800 77900 77900 78000 78100 78200 78300 78400 78500 78600 78700 78800 78900 78900 79000 79100 79200 79300 79400 79500 79600 79700 79800 79800 79900 80000 80100 80200 80300 80400 80500 80600 80700 80800 80900 80900 81000 81100 81200 81300 81400 81500 81600 81700 81800 81900 81900 82000 82100 82200 82300 82400 82500 82600 82700 82800 82900 82900 83000 83100 83200 83300 83400 83500 83600 83700 83800 83900 83900 84000 84100 84200 84300 84400 84500 84600 84700 84800 84900 84900 85000 85100 85200 85300 85400 85500 85600 85700 85800 85900 85900 86000 86100 86200 86300 86400 86500 86600 86700 86800 86900 86900 87000 87100 87200 87300 87400 87500 87600 87700 87800 87800 87900 88000 88100 88200 88300 88400 88500 88600 88700 88800 88800 88900 89000 89100 89200 89300 89400 89500 89600 89700 89700 89800 89900 89900 90000 90100 90200 90300 90400 90500 90600 90700 90800 90900 90900 91000 91100 91200 91300 91400 91500 91600 91700 91800 91900 91900 92000 92100 92200 92300 92400 92500 92600 92700 92800 92900 92900 93000 93100 93200 93300 93400 93500 93600 93700 93800 93900 93900 94000 94100 94200 94300 94400 94500 94600 94700 94800 94900 94900 95000 95100 95200 95300 95400 95500 95600 95700 95800 95900 95900 96000 96100 96200 96300 96400 96500 96600 96700 96800 96900 96900 97000 97100 97200 97300 97400 97500 97600 97700 97800 97800 97900 98000 98100 98200 98300 98400 98500 98600 98700 98800 98800 98900 98900 99000 99100 99200 99300 99400 99500 99600 99700 99700 99800 99900 99900 100000 100100 100200 100300 100400 100500 100600 100700 100800 100900 100900 101000 101100 101200 101300 101400 101500 101600 101700 101800 101900 101900 102000 102100 102200 102300 102400 102500 102600 102700 102800 102900 102900 103000 103100 103200 103300 103400 103500 103600 103700 103800 103900 103900 104000 104100 104200 104300 104400 104500 104600 104700 104800 104900 104900 105000 105100 105200 105300 105400 105500 105600 105700 105800 105900 105900 106000 106100 106200 106300 106400 106500 106600 106700 106800 106900 106900 107000 107100 107200 107300 107400 107500 107600 107700 107800 107800 107900 108000 108100 108200 108300 108400 108500 108600 108700 108800 108800 108900 108900 109000 109100 109200 109300 109400 109500 109600 109700 109700 109800 109900 109900 110000 110100 110200 110300 110400 110500 110600 110700 110800 110900 110900 111000 111100 111200 111300 111400 111500 111600 111700 111800 111900 111900 112000 112100 112200 112300 112400 112500 112600 112700 112800 112900 112900 113000 113100 113200 113300 113400 113500 113600 113700 113800 113900 113900 114000 114100 114200 114300 114400 114500 114600 114700 114800 114800 114900 115000 115100 115200 115300 115400 115500 115600 115700 115800 115900 115900 116000 116100 116200 116300 116400 116500 116600 116700 116800 116900 116900 117000 117100 117200 117300 117400 117500 117600 117700 117800 117800 117900 117900 118000 118100 118200 118300 118400 118500 118600 118700 118800 118800 118900 118900 119000 119100 119200 119300 119400 119500 119600 119700 119700 119800 119900 119900 120000 120100 120200 120300 120400 120500 120600 120700 120800 120800 120900 120900 121000 121100 121200 121300 121400 121500 121600 121700 121800 121800 121900 121900 122000 122100 122200 122300 122400 122500 122600 122700 122800 122800 122900 122900 123000 123100 123200 123300 123400 123500 123600 123700 123800 123800 123900 123900 124000 124100 124200 124300 124400 124500 124600 124700 124800 124800 124900 124900 125000 125100 125200 125300 125400 125500 125600 125700 125800 125800 125900 125900 126000 126100 126200 126300 126400 126500 126600 126700 126800 126800 126900 126900 127000 127100 127200 127300 127400 127500 127600 127700 127800 127800 127900 127900 128000 128100 128200 128300 128400 128500 128600 128700 128800 128800 128900 128900 129000 129100 129200 129300 129400 129500 129600 129700 129800 129800 129900 129900 130000 130100 130200 130300 130400 130500 130600 130700 130800 130800 130900 130900 131000 131100 131200 131300 131400 131500 131600 131700 131800 131800 131900 131900 132000 132100 132200 132300 132400 132500 132600 132700 132800 132800 132900 132900 133000 133100 133200 133300 133400 133500 133600 133700 133800 133800 133900 133900 134000 134100 134200 134300 134400 134500 134600 134700 134800 134800 134900 134900 135000 135100 135200 135300 135400 135500 135600 135700 135800 135800 135900 135900 136000 136100 136200 136300 136400 136500 136600 136700 136800 136800 136900 136900 137000 137100 137200 137300 137400 137500 137600 137700 137800 137800 137900 137900 138000 138100 138200 138300 138400 138500 138600 138700 138800 138800 138900 138900 139000 139100 139200 139300 139400 139500 139600 139700 139800 139800 139900 139900 140000 140100 140200 140300 140400 140500 140600 140700 140800 140800 140900 140900 141000 141100 141200 141300 141400 141500 141600 141700 141800 141800 141900 141900 142000 142100 142200 142300 142400 142500 142600 142700 142800 142800 142900 142900 143000 143100 143200 143300 143400 143500 143600 143700 143800 143800 143900 143900 144000 144100 144200 144300 144400 144500 144600 144700 144800 144800 144900 144900 145000 145100 145200 145300 145400 145500 145600 145700 145800 145800 145900 145900 146000 146100 146200 146300 146400 146500 146600 146700 146800 146800 146900 146900 147000 147100 147200 147300 147400 147500 147600 147700 147800 147800 147900 147900 148000 148100 148200 148300 148400 148500 148600 148700 148800 14